Tocilizumab
What's New
Last Posted: Mar 04, 2023
- Emergent high fatality lung disease in systemic juvenile arthritis.
Saper Vivian E, et al. Annals of the rheumatic diseases 2019 0 (12) 1722-1731 - Interleukin-6 receptor genetic variation and tocilizumab treatment response to COVID-19
AA Almarzook, MEDRXIV, April 27, 2021 - Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
REMAP CAP investigators, NEJM, April 21, 2021 - Prognostic and predictive biomarkers in patients with COVID-19 treated with tocilizumab in a randomised controlled trial
J Tom, MEDRXIV, December 26, 20320
Content Summary
Common RCH Related Topics
- Attention Deficit/Hyperactivity Disorder
- Autism
- Birth Defects
- Carrier Testing
- Cerebral Palsy
- Congenital heart defects
- Pregnancy loss
- Developmental Disabilities
- Gestational Diabetes
- Hearing loss
- Neural tube defects
- Infant Mortality
- Infertility
- Learning disability
- Newborn Screening
- Preeclampsia
- Prematurity
- Prenatal Testing
- Stillbirth
- Sudden Infant Death Syndrome
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by Public Health Genomics Branch to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2024
- Content source:


